These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35831917)

  • 1. Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
    Liu K; Zheng W; Chen Y; Tang M; Li D; Deng D; Yang T; Zhang C; Liu J; Yuan X; Shi M; Li X; Guo Y; Zhou Y; Zhao M; Chen L
    J Med Chem; 2022 Jul; 65(14):9893-9917. PubMed ID: 35831917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.
    Zhou H; McGowan MA; Lipford K; Christopher M; Fradera X; Witter D; Lesburg CA; Li C; Methot JL; Lampe J; Achab A; Shaffer L; Goldenblatt P; Shah S; Bass A; Schroeder G; Chen D; Zeng H; Augustin MA; Katz JD
    Bioorg Med Chem Lett; 2020 Jan; 30(1):126715. PubMed ID: 31757666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation.
    Tao Q; Chen Y; Liang X; Hu Y; Li J; Fang F; Wang H; Meng C; Liang J; Ma X; Gui S
    Eur J Med Chem; 2020 Apr; 191():112143. PubMed ID: 32078865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies.
    Zhang J; Jiang H; Lin S; Wu D; Tian H; Jiang L; Cui Y; Jin J; Chen X; Xu H
    J Med Chem; 2022 Jun; 65(11):8011-8028. PubMed ID: 35609190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor.
    Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Moritomo A; Kubo S; Nakamura K; Yamagami K; Hamakawa N; Yokoo K; Fukahori H
    Bioorg Med Chem; 2018 Aug; 26(14):3917-3924. PubMed ID: 29907471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Indazoles as Potent and Selective PI3Kδ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma.
    Qi J; Wang W; Tang Y; Lou S; Wang J; Yuan T; He Q; Yang B; Zhu H; Cui S
    J Med Chem; 2022 Mar; 65(5):3849-3865. PubMed ID: 35191698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Potent and Selective PI3Kδ Inhibitor (
    Shukla MR; Patra S; Verma M; Sadasivam G; Jana N; Mahangare SJ; Vidhate P; Lagad D; Tarage A; Cheemala M; Kulkarni C; Bhagwat S; Chaudhari VD; Sayyed M; Pachpute V; Phadtare R; Gole G; Phukan S; Sunkara B; Samant C; Shingare M; Naik A; Trivedi S; Marisetti AK; Reddy M; Gholve M; Mahajan N; Sabde S; Patil V; Modi D; Mehta M; Nigade P; Tamane K; Tota S; Goyal H; Volam H; Pawar S; Ahirrao P; Dinchhana L; Mallurwar S; Akarte A; Bokare A; Kanhere R; Reddy N; Koul S; Dandekar M; Singh M; Bernstein PR; Narasimham L; Bhonde M; Gundu J; Goel R; Kulkarni S; Sharma S; Kamboj RK; Palle VP
    J Med Chem; 2020 Dec; 63(23):14700-14723. PubMed ID: 33297683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
    Jia H; Dai G; Su W; Xiao K; Weng J; Zhang Z; Wang Q; Yuan T; Shi F; Zhang Z; Chen W; Sai Y; Wang J; Li X; Cai Y; Yu J; Ren P; Venable J; Rao T; Edwards JP; Bembenek SD
    J Med Chem; 2019 May; 62(10):4936-4948. PubMed ID: 31033293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors.
    Patel L; Chandrasekhar J; Evarts J; Haran AC; Ip C; Kaplan JA; Kim M; Koditek D; Lad L; Lepist EI; McGrath ME; Novikov N; Perreault S; Puri KD; Somoza JR; Steiner BH; Stevens KL; Therrien J; Treiberg J; Villaseñor AG; Yeung A; Phillips G
    J Med Chem; 2016 Apr; 59(7):3532-48. PubMed ID: 26980109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon.
    Yang X; Bai H; Yuan X; Yang X; Liu Y; Guo M; Hu N; Jiang B; Lian Z; Ma Z; Wang J; Sun X; Zhang T; Su D; Wu Y; Li J; Wang F; Wang Z; Wang L; Liu X; Song X
    Neoplasia; 2024 Nov; 57():101053. PubMed ID: 39260132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Optimization of Pyridazinones as PI3Kδ Selective Inhibitors for Administration by Inhalation.
    Bruno P; Micoli A; Corsi M; Pala D; Guariento S; Fiorelli C; Ronchi P; Fioni A; Gallo PM; Marenghi G; Bertolini S; Capacchi S; Mileo V; Biagetti M; Capelli AM
    J Med Chem; 2024 Jul; 67(13):11103-11124. PubMed ID: 38907711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel pyrido[3,2-d]pyrimidine derivatives as selective and potent PI3Kδ inhibitors.
    Bai H; Sun J; Lei H; Zhang SQ; Yuan B; Ma M; Xin M
    Drug Dev Res; 2023 Dec; 84(8):1709-1723. PubMed ID: 37732677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
    Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
    Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments.
    Lei H; Duan W; Zhang SQ; Feng Y; Ma M; Yuan B; Xin M
    Bioorg Chem; 2023 Sep; 138():106594. PubMed ID: 37186998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
    Gong YP; Tang LQ; Liu TS; Liu ZP
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models.
    Moreno O; Wood J
    Target Oncol; 2019 Oct; 14(5):603-611. PubMed ID: 31506873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
    Liu L; Li X; Cheng Y; Wang L; Yang H; Li J; He S; Shuangjie Wu ; Yin Q; Xiang H
    Eur J Med Chem; 2019 Feb; 164():304-316. PubMed ID: 30605829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.